CEO Leon O Jr Moulder bought 60,000 shares ($1.0M) at $16.88 on 2026-05-18, tripling holdings to 96,928 shares amid -62.1% decline from 52-week high.
Leon O Jr Moulder, CEO of Zenas BioPharma, purchased 60,000 shares for $1,012,800.00 at $16.88, expanding his holdings by 162.5% to 96,928 shares. The purchase occurs in a context of significant price deterioration: the stock trades at $16.91, down 62.1% from its 52-week high of $44.60 and down 22.5% over the past 30 days. Prior buys at ZBIO show mixed timing—4 of 5 were well-timed at the 90-day mark, with his two most recent purchases on 2026-04-29 and 2026-04-28 returning +4.1% and +1.8% at 90 days respectively. However, fundamentals remain concerning: the company reported $0.00 revenue in the latest quarter and a net loss of $-80,987,000.00 for the full year, despite revenue growth of 100.0% year-over-year, indicating early-stage biotech with no current commercial revenue. The scale of this purchase relative to prior trading activity and his expanded concentration warrant scrutiny into whether this reflects informed conviction or response to depressed valuation in a loss-making firm.